ABSTRACT
INTRODUCTION

Preeclampsia
(PE) is a multisystem disorder involving vasoconstriction and hypertension in the mother. There are inconsistent reports on whether there is an association between preeclampsia and thrombophilia (1) . Thrombophilia is a term used to describe a heterogenous group of coagulation abnormalities (acquired or inherited) that are generally associated with increased risk of arterial and venous thrombosis (2) .
The most common inherited thrombophilic disorders during pregnancy are mutations in factor V Leiden (FVL), prothrombin gene, and tetrahydrofolate reductase (MTHFR). During the past 2 decades, epidemiologic and case-control studies have evaluated the association between thrombophilias and adverse pregnancy outcome (APO), specifically, preeclampsia and intrauterine fetal growth restriction (IUGR) (3) . Unfortunately, the results of previous studies are controversial, and a systematic review of the association between maternal thrombophilia and PE has not led to definite conclusions (4) . The etiology and pathogenesis of hypertensive disorders of pregnancy, including pre-eclampsia remain unknown. It is thought that genetic predisposition and immune maladaptation contribute to placental ischemia and consequent abnormalities of the maternal vascular endothelium, activation of the coagulation systems. Venous and possibly arterial diseases have resulted from many polymorphisms in various prothrombotic genes, including G1691A in FVL, prothrombin G20210A and MTHFR C677T
(5) . The aim of the present study is to determine the relationship of mutations of factor V Leiden, prothrombin and methylene tetrahydrofolate reductase genes in Egyptian preeclamptic patients.
SUBJECTS & METHODS
The present study included 56 preeclamptic women and 48 normal pregnant women attending the Obstetric Outpatient Clinic, Mansoura University Hospital. Five ml. venous blood samples were collected from each subject in polyethylene tubes containing EDTA as an anticoagulant for DNA extraction. The generation of DNA purification capture column kit (Gentra systems USA) was used for DNA extraction.
FVL (G1691A) and prothrombin (G20210A) gene mutations were analyzed using a multiplex allele specific PCR amplification. The DNA extracted from all cases was also subjected to amplification of a region of factor IX gene as an internal control for assessment of the quality of the extracted DNA. Each PCR was performed with 300 ng of DNA, 200 mmol/L of each dNTP, 500 nmol/L of each primer and 2. (WT)  5′-GCAGATCCCTGGACAGACG-3′  FVL mutant (MT)  5′-GCAGATCCCTGGACAGACA-3′  PT common  5′-TCTAGAAACAGTTGCCTGGCAG-3′  PT Wild (WT)  5′-GCACTGGGAGCATTGAGGATC-3′  PT mutant (MT)  5′-GCACTGGGAGCATTGAGGATT-3′  FIX1  5′-CTCCTGCAGCATTGAGGGAGATGGACATT-3′  FIX 2 5′-CTCGAATTCGGCAAGCATACTCAATGTAT-3′
The regions containing 2 RFLPs within the MTHFR gene were amplified with Taq DNA polymerase. For evaluation of MTHFR C677T polymorphism, the polymorphic site was amplified with primers (8) :
For PCR, the following procedure was used: initial denaturation for 3 minutes at 95 ο C, and then 5 cycles were performed as follows: 94 ο C for 1 minute, 64 
RESULTS
In the present study 56 patients with preeclampsia were used and 48 healthy pregnant females were also used as a control group. As shown in table (2), there is significant association between prothrombin gene mutations, p= < 0.0001 (8 out of 56 preeclamptic pregnant patients 14.28%) compared with pregnant control groups (zero out of 48 subjects 0 %). Also, significant association was founded between FVL gene mutations p= 0.0185 (22 out of 56 pregnant patients with preeclampsia 39.22%) compared with pregnant control groups (1 out of 48 pregnant control groups 2.08%). As shown in table (3), there is no significant association between MTHR T allele, p= 0.6525 (37 out of 112 preeclamptic pregnant patients 33.04%) compared with pregnant control groups (28 out of 96 subjects 29.17%).
The relative risk of preeclampsia with patients carrying T allele as compared with control subjects were 1.1981 (OR=1.1981, P=0.6525). As shown in table (4), there is no significant association between MTHR C allele, p= 0.7237 (44 out of 112 preeclamptic pregnant patients 58.22%) compared with pregnant control groups (43 out of 96 subjects 44.80%).
The relative risk of preeclampsia with patients carrying C allele as compared with control subjects were 0.9350 (OR= 0.9350, P= 0.7237). 
who, demonstrated that women who are carriers of factor V or prothrombin mutations are at higher risk for late fetal loss than noncarriers.
Dirula et al. (19) had found higher prevalence of FVL mutation in women with preeclampsia compared with control subjects. Grandone et al. (20) reported that the prothrombin gene mutation was significantly more frequent in preeclamptic patients than in controls.
The presence of either of these mutations was associated with no significant increased risk for RFL in first trimester. Genetic thrombophilic defects are common in women with RFL and are associated with late fetal loss. This association is manifest by FVL rather than total number of defects involved (21) . The findings of Kahn et al. (22) do not indicate an increased risk of preeclampsia among women with any of the three studied inherited thrombophilias. The increase in placental underperfusion among women with preeclampsia seems to be associated with low plasma folate levels but not with the three studied thrombophilias examined. Also, Morrison et al. (23) concluded that these prothrombotic genotypes are not associated with the development of PE or GH in their population Also, studies of the factor V mutation have revealed an association between that mutation and first-or second-trimester fetal loss (24) . Carriers of that mutation also seem to be at a higher risk for third-trimester fetal loss than noncarriers, although this is not a consistent finding (25) . However, the prothrombin-gene mutation is associated with fetal death is not known (15) . Resistance to activated protein C caused by an adenine-to-guanine mutation at nucleotide 506 in the factor V gene has been linked with an increased risk of venous thromboembolism (26) . Homozygosity for the mutation of cytosine to thymine at nucleotide 677 in the gene encoding MTHFR results in decreased synthesis of 5-MTHF that results in increase in plasma homocysteine concentrations producing a risk factor for venous and arterial thrombosis (27) . Women who carried this mutation are at higher risk for various obstetrical complications, such as preeclampsia, abruptio placentas, intrauterine growth retardation, and late fetal loss (28) . A point mutation at nucleotide 1691 in exon 10 of the Factor V gene makes factor Va resistant to proteolytic inactivation by activated protein C (29) leading to physiological hypercoagulation in pregnancy and this may contribute to increased thrombus formation in the placenta and thus may be a hereditary risk factor for preeclampsia (30) . On the other hand, there was no difference in thrombophilic mutations between preeclamptic patients and normal pregnant women. Therefore, it would be suggested that preeclamptic patients should not be tested for thrombophilia (31) . Kupferminc et al. (28) stated that, there was no difference in the prevalence of genetic risk factors for thrombosis in women with preeclampsia compared with control subjects. Also, Lindqvist et al. (32) found no difference in prevalence for this mutation in preeclampsia or IUGR patients. This finding is supported by the findings of Livingston et al.
(33) , who found no association of maternal or fetal genetic polymorphisms (Factor V Leiden, Factor II, MTHFR) and severe preeclampsia.
In the population analyzed, the presence of the genotype risk factors alone does not seem to be associated with the development of preeclampsia even in the severe presentation form. However, the interactions between more than one thrombophilic gene (MTHFR, F II, FVL and PAI-1) polymorphisms were involved in the development of preeclampsia (34) . 
